DRUG TRANSPORTERS IN THE INTESTINE - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 514

59. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH,
Schinkel AH. 2003. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure
to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res
63(19):6447-6452.
60. Matsumoto S, Saito H, Inui K. 1994. Transcellular transport of oral cephalosporins in
human intestinal epithelial cells, Caco-2: interaction with dipeptide transport systems in
apical and basolateral membranes. J Pharmacol Exp Ther 270(2):498-504.
61. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K. 1999. Functional characteristics of
basolateral peptide transporter in the human intestinal cell line Caco-2. Am J Physiol 276(6
Pt 1):G1435-G1441.
62. Tseng E, Kamath A, Morris ME. 2002. Effect of organic isothiocyanates on the P-
glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharm Res
19(10):1509-1515.
63. Mao Q, Deeley RG, Cole SP. 2000. Functional reconstitution of substrate transport by
purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. J Biol
Chem 275(44):34166-34172.
64. Twentyman PR, Bleehen NM. 1991. Resistance modification by PSC-833, a novel nonim-
munosuppressive cyclosporin [corrected]. Eur J Cancer 27(12):1639-1642.
65. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen
JH. 1997. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein
blocker SDZ PSC 833. Br J Cancer 76(9):1181-1183.
66. Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. 2004. Efficacy
of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest
New Drugs 22(3):219-229.
67. Sinko PJ, Kunta JR, Usansky HH, Perry BA. 2004. Differentiation of gut and hepatic
first pass metabolism and secretion of saquinavir in ported rabbits. J Pharmacol Exp Ther
310(1):359-366.
68. Wu CY, Benet LZ. 2003. Disposition of tacrolimus in isolated perfused rat liver: in-
fluence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos 31(11):1292-
1295.
69. Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE.
2001. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of
6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 7(6):1610-
1617.
70. van Asperen J, van Tellingen O, Beijnen JH. 2000. The role of mdr1a P-glycoprotein in
the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab
Dispos 28(3):264-267.
71. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The
drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease
inhibitors. J Clin Invest 101(2):289-294.
72. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K,
Tsuji A. 1999. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in
mdr1a knockout mice. Pharm Res 16(8):1213-1218.
73. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-
glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug
Metab Dispos 27(8):866-871.